We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Hvivo Plc | LSE:HVO | London | Ordinary Share | GB00B9275X97 | ORD 0.1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.20 | -0.71% | 27.80 | 27.50 | 28.50 | 28.00 | 27.75 | 28.00 | 606,599 | 16:35:07 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 56.04M | 16.12M | 0.0239 | 11.72 | 189.02M |
TIDMHVO
RNS Number : 9346J
hVIVO plc
23 August 2019
hVIVO plc
("hVIVO" or the "Company")
Notice of Interim Results
London, UK 23 August 2019: hVIVO plc (AIM: HVO), an industry leading clinical development services business pioneering human disease models based upon viral challenge, will announce its interim financial results for the six months ended 30 June 2019 on Thursday 19 September 2019.
A presentation and webcast for analysts will be held at 11.00am BST at the offices of FTI Consulting, 200 Aldersgate, Aldersgate Street, London, EC1A 4HD, with registration and coffee from 10.45am. A webcast recording of the event will be available on the Company's website.
For further information please contact:
hVIVO plc Trevor Phillips (Executive Chairman) +44 207 756 1300 Fleur Wood (EVP, Investor Relations & Communications) Numis Securities Limited +44 207 260 1000 Freddie Barnfield / Huw Jeremy (Nominated Adviser) James Black (Corporate Broking) FTI Consulting Simon Conway / Victoria Foster Mitchell +44 203 727 1000
Notes to Editors:
hVIVO plc ("hVIVO") is pioneering a human-based clinical trial platform to accelerate drug and vaccine development in respiratory and infectious diseases. Leveraging human disease models in flu, RSV, HRV and respiratory indications, the hVIVO platform captures disease in motion, illuminating the entire disease life cycle from healthy to sick and back to health. Based in the UK, market leader hVIVO has conducted more than 50 clinical studies and inoculated over 2500 volunteers.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
NORLIFEATEIFFIA
(END) Dow Jones Newswires
August 23, 2019 02:00 ET (06:00 GMT)
1 Year Hvivo Chart |
1 Month Hvivo Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions